Clinical Trials In Cincinnati

Discover hundreds of clinical trials in Cincinnati.
Search clinical trials in Cincinnati by condition or phase.

e.g. Respiratory Diseases

Cincinnati•Healthy volunteers: No

Filter results

Results: 1,259

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Recruiting

Phase 3

Sponsor:

H. Lundbeck A/S

Location:

Cincinnati, Akron, Stamford, Gulf Breezeshow 10 more

Code:

NCT05897320

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Eptinezumab

Placebo

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Recruiting

Phase 2

Phase 3

Sponsor:

Regeneron Pharmaceuticals

Location:

Cincinnati, Mentor, Columbus, Phoenixshow 40 more

Code:

NCT05831176

Conditions

Eosinophilic Gastritis

Eosinophilic Duodenitis

Eosinophilic Gastrointestinal Disease

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Dupilumab Dose 1

Dupilumab Dose 2

Matching Placebo

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recruiting

Phase 2

Sponsor:

National Cancer Institute (NCI)

Location:

Cincinnati, West Chester, Columbus, Bethesda

Code:

NCT06311227

Conditions

Recurrent Hairy Cell Leukemia

Recurrent Hairy Cell Leukemia Variant

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Computed Tomography

Magnetic Resonance Imaging

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Recruiting

Phase 3

Sponsor:

AstraZeneca

Location:

Cincinnati, Phoenix, Little Rock, Los Angelesshow 24 more

Code:

NCT05583227

Conditions

Eosinophilic Esophagitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Placebo

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting

Phase 3

Sponsor:

Sanofi

Location:

Cincinnati, Dayton, Columbus, Centervilleshow 61 more

Code:

NCT06141473

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Frexalimab

Teriflunomide

Placebo infusion

Placebo tablet

MRI contrast-enhancing agents

Consolidation of First-Line MRD+ Remission with Cema-cel in Patients with LBCL

Recruiting

Phase 2

Sponsor:

Allogene Therapeutics

Location:

Cincinnati, Berkeley, Denver, Newarkshow 14 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

Modifiers of Disease Severity in Cerebral Cavernous Malformations

Recruiting

Sponsor:

UCLA

Location:

Cincinnati, Phoenix, San Francisco, Chicagoshow 3 more

Code:

NCT01764529

Conditions

Cavernous Angioma, Familial

Cerebral Cavernous Malformations

Cerebral Cavernous Hemangioma

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Recruiting

Phase 3

Sponsor:

Palvella Therapeutics, Inc.

Location:

Cincinnati, Cleveland, Palo Alto, New Brightonshow 6 more

Code:

NCT06239480

Conditions

Microcystic Lymphatic Malformation

Eligibility Criteria

Sex: All

Age: 6+

Healthy Volunteers: Not accepted

Interventions

QTORIN 3.9% Rapamycin Anhydrous Gel

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Recruiting

Phase 1

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

Cincinnati

Code:

NCT03826992

Conditions

Leukemia

Eligibility Criteria

Sex: All

Age: 1 - 39

Healthy Volunteers: Not accepted

Interventions

Vyxeos

Venetoclax

Endovascular Therapy for Low NIHSS Ischemic Strokes

Recruiting

Phase 2

Phase 3

Sponsor:

Emory University

Location:

Cincinnati, Columbus, Cleveland, Torranceshow 23 more

Code:

NCT04167527

Conditions

Cerebral Ischemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device

Initial medical management (iMM)

e.g. Respiratory Diseases

Cincinnati•Healthy volunteers: No

Filter results

Results: 1,259

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Recruiting

Phase 3

Sponsor:

H. Lundbeck A/S

Location:

Cincinnati, Akron, Stamford, Gulf Breezeshow 10 more

Code:

NCT05897320

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Eptinezumab

Placebo

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Recruiting

Phase 2

Phase 3

Sponsor:

Regeneron Pharmaceuticals

Location:

Cincinnati, Mentor, Columbus, Phoenixshow 40 more

Code:

NCT05831176

Conditions

Eosinophilic Gastritis

Eosinophilic Duodenitis

Eosinophilic Gastrointestinal Disease

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Dupilumab Dose 1

Dupilumab Dose 2

Matching Placebo

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recruiting

Phase 2

Sponsor:

National Cancer Institute (NCI)

Location:

Cincinnati, West Chester, Columbus, Bethesda

Code:

NCT06311227

Conditions

Recurrent Hairy Cell Leukemia

Recurrent Hairy Cell Leukemia Variant

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Computed Tomography

Magnetic Resonance Imaging

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Recruiting

Phase 3

Sponsor:

AstraZeneca

Location:

Cincinnati, Phoenix, Little Rock, Los Angelesshow 24 more

Code:

NCT05583227

Conditions

Eosinophilic Esophagitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Placebo

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting

Phase 3

Sponsor:

Sanofi

Location:

Cincinnati, Dayton, Columbus, Centervilleshow 61 more

Code:

NCT06141473

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Frexalimab

Teriflunomide

Placebo infusion

Placebo tablet

MRI contrast-enhancing agents

Consolidation of First-Line MRD+ Remission with Cema-cel in Patients with LBCL

Recruiting

Phase 2

Sponsor:

Allogene Therapeutics

Location:

Cincinnati, Berkeley, Denver, Newarkshow 14 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

Modifiers of Disease Severity in Cerebral Cavernous Malformations

Recruiting

Sponsor:

UCLA

Location:

Cincinnati, Phoenix, San Francisco, Chicagoshow 3 more

Code:

NCT01764529

Conditions

Cavernous Angioma, Familial

Cerebral Cavernous Malformations

Cerebral Cavernous Hemangioma

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Recruiting

Phase 3

Sponsor:

Palvella Therapeutics, Inc.

Location:

Cincinnati, Cleveland, Palo Alto, New Brightonshow 6 more

Code:

NCT06239480

Conditions

Microcystic Lymphatic Malformation

Eligibility Criteria

Sex: All

Age: 6+

Healthy Volunteers: Not accepted

Interventions

QTORIN 3.9% Rapamycin Anhydrous Gel

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Recruiting

Phase 1

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

Cincinnati

Code:

NCT03826992

Conditions

Leukemia

Eligibility Criteria

Sex: All

Age: 1 - 39

Healthy Volunteers: Not accepted

Interventions

Vyxeos

Venetoclax

Endovascular Therapy for Low NIHSS Ischemic Strokes

Recruiting

Phase 2

Phase 3

Sponsor:

Emory University

Location:

Cincinnati, Columbus, Cleveland, Torranceshow 23 more

Code:

NCT04167527

Conditions

Cerebral Ischemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device

Initial medical management (iMM)